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Since its discovery in 1994, Kaposi’s sarcoma-associated herpesvirus (KSHV) has been associated with lymphoproliferative
disorders, particularly in patients infected with human immunodeﬁciency virus (HIV). The disorders most strongly linked to
KSHV are multicentric Castleman’s Disease (MCD), primary eﬀusion lymphoma, and diﬀuse large B-cell lymphomas. We report
an unusual case of KSHV-associated lymphoma in an HIV-infected patient manifesting with myocardial and central nervous
system involvement. We discuss this case in the context of increasing array of KSHV-associated lymphomas. In the HIV-infected
patient with a mass lesion, a history of cutaneous Kaposi’s sarcoma and prolonged immunosuppression should alert clinicians as
to the possibility of KSHV-associated lymphoproliferative disorders, in order to establish a timely diagnosis.
1.CaseReport
A 46-year-old man with HIV and a history of cutaneous
Kaposi’s sarcoma presented with left eyelid droop and left-
sided facial numbness ﬁve days after restarting antiretroviral
therapy following a long hiatus. He was diagnosed with HIV
21 years prior and had a nadir CD4 cell count of 107. His
CD4 cell count when he restarted his antiretroviral regimen
was 159 cells/mm3, viral load 511,000c/mL. He had been
intermittently compliant with antiretroviral therapy in the
past and since resumption of therapy. In 2005, he had a
recurrence of Kaposi’s sarcoma and received ﬁve cycles of
paclitaxel with clinical remission by 2006. Physical examina-
tion was otherwise unremarkable at the time and magnetic
resonance imaging (MRI) of the brain was read as having
no signiﬁcant abnormalities. His symptoms initially were
stable, but in the subsequent two months, they worsened,
with hypoesthesia and paresthesia over all three branches of
the trigeminal nerve on the left, severe headaches, ataxia,
dysarthria, and dysphagia. He also began to experience
fatigue, weight loss, and night sweats. A repeat MRI revealed
enhancingleptomeningealmasseswithassociatedmasseﬀect
involving the trigeminal nerve, middle cerebellar peduncle,
pons,andupperspinalcord.ReviewofhispriorMRIshowed
a suggestion of enhancement of the left trigeminal nerve
intradurally.
A lumbar puncture revealed elevated protein (205g/dL),
slightly depressed glucose (45g/dL), with 106 leukocytes
(32% lymphocytes, 26% monocytes, and 42% unclassiﬁed
cells), and no erythrocytes. Cerebral spinal ﬂuid (CSF)
cytology was notable for atypical appearing cells, which were
suspicious for, but not suﬃcient for a primary diagnosis of
malignancy (see Figure 2(a)). CSF ﬂow cytometry demon-
strated no clonal B- or T-cell populations, and IGH gene
rearrangement was not detected by PCR. CSF PCR for EBV
was negative.2 AIDS Research and Treatment
Figure 1: PET-CT demonstrated a focus of avidity at the known
cerebellopontine lesion, as well as in the posterior inferior wall and
papillary muscle of the left ventricle of the heart.
A bone marrow biopsy was unremarkable and core
needle biopsy of a modestly enlarged retroperitoneal lymph
node showed no evidence of lymphoproliferative disease.
There was no evidence of pleural, peritoneal, or pericardial
eﬀusions on computed tomography and ultrasound studies.
A positron emission tomography with computed tomog-
raphy (PET/CT) was then performed and demonstrated
increased uptake at the known cerebellopontine lesion, as
well as in the posterior inferior wall and papillary muscle of
the left ventricle of the heart (Figure 1). An endomyocardial
biopsy of the left ventricle was performed via left heart
catheterization. Pathology revealed large atypical discohesive
cells inﬁltrating the myocardium. Immunostains of the
atypical lymphoid cells were strongly KSHV+ (Figure 2),
MUM1/IRF4+, CD79a rare+, CD20−. In situ hybridization
for Epstein-Barr virus (EBV) using a probe for EBER showed
no staining. Comparison with the CSF specimens showed
that these atypical cells were morphologically similar to the
suspicious cells in the CSF (Figure 2(a)).
A preliminary diagnosis of large B-cell lymphoma was
madebasedonmorphologicappearance,andthepatientwas
initiated on treatment with R-CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone) along
with intrathecal methotrexate, cytarabine, and hydrocorti-
sone for the leptomeningeal disease. He was observed on
telemetry for one week without cardiac ectopy and was dis-
charged home. One day following discharge, he had syncope
andwasfoundtobeinventriculartachycardiawithpreserved
blood pressure, for which he was treated with lidocaine
and amiodarone with successful conversion to sinus rhythm.
CD20 staining on his pathology returned negative and so
treatment with cycle 2 was changed to EPOCH (etoposide,
prednisone, vincristine, cyclophosphamide, and doxoru-
bicin) without rituximab. High-dose systemic methotrexate
was included to treat the CNS disease. Six weeks into
treatment, restaging PET CT imaging showed no persistent
FDG-avid disease of the heart, and MRI showing signiﬁcant
resolution of his intracranial tumor. Spinal ﬂuid examina-
tion demonstrated no persistent circulating disease in the
CSF. Clinically, his headaches, dysarthria, and dysphagia
improved, but he still had numbness of his left face along the
V1 and V2 distribution of the trigeminal nerve along with an
upper motor facial nerve palsy on the left. Some residual gait
ataxia was notable on examination.
2. Discussion
Kaposi’s sarcoma was ﬁrst described in elderly European
men in 1872 by Moritz Kaposi, and lymphomatous eﬀusions
were identiﬁed in patients with HIV in the late 1980s [1],
but the common viral etiology was not identiﬁed until
1994 [2]. Since that time, an array of lymphoproliferative
manifestations of KSHV infection have been recognized,
with most cases being identiﬁed in patients with HIV
infection. The most well-characterized diseases are multi-
centric Castleman’s disease (MCD) [3, 4], diﬀuse large B-
cell lymphomas arising from MCD, and primary eﬀusion
lymphoma (PEL), for which KSHV detection is the sine qua
non [5]. More recently, cases of “solid” or “extracavitary”
lymphomas with PEL-like pathologic features have been
reported[6].Thereisconﬂictingevidenceastowhetherthese
tumors carry a worse prognosis than PEL. Chadburn et al.
described eight patients with KSHV-solid lymphomas that
were indistinguishable on immunophenotype and genotype
from PEL, with a median survival of 11 months compared
with 3 months for PEL [6]. Simonelli et al. described
three patients with solid-variant PEL, all of whom died
within a month of diagnosis (median survival of 22 days)
[7]. Successful treatment with antiretroviral therapy and
chemotherapy has been reported [6, 8].
The patient we report here had a large B-cell lymphoma
with features of extracavitary PEL. In the initial description
of PEL, all tumors stained positive for Epstein-Barr virus
(EBV) in addition to KSHV, and subsequent case reports
have conﬁrmed EBV coexpression in the majority of cases
[6, 9, 10]. Our patient’s tumor did not, consistent with
prior reports suggesting that lack of EBV expression may
occasionally be seen in extracavitary PEL [11].
KSHV-positive lymphomas have been recovered from a
variety of solid organs, including the heart, bowel, lymph
nodes, spermatic cord, skin, soft tissues, and spleen [12–
14]. CNS involvement as is present in this case has rarely
been reported in PEL, though it is common in other HIV-
associated lymphomas. In addition, although immunosup-
pression is well recognized as a risk factor in the devel-
opment of certain cardiac lymphomas, to our knowledge
KSHV+ lymphoma involving the myocardium has not been
described previously. This case highlights the importance
of immunohistochemistry, HHV8, and EBV testing in the
diagnosis of HIV-associated lymphomas, as morphologically
this disease would otherwise be classiﬁed as diﬀuse large B-
cell lymphoma, not otherwise speciﬁed.
The potential utility of antivirals in treatment of KSHV-
associated lymphoproliferative disorders is an area of active
interest. Ganciclovir has been shown to inhibit KSHVAIDS Research and Treatment 3
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Figure 2: (a) Cerebrospinal ﬂuid contains rare large, atypical cells with lobated nuclei and abundant basophilic cytoplasm; scattered smaller
nonneoplastic cells are also present. (b)–(d) Endomyocardial biopsy. Microscopic examination by hematoxylin and eosin stain shows an
atypical lymphoid proliferation inﬁltrating the myocardium (b). Higher power revealed large atypical discohesive cells with few admixed
eosinophils (c). Large lymphoid cells stained avidly for Kaposi’s sarcoma herpesvirus by immunostain (d).
replication, and there have been case reports of its successful
used alone or in adjunct to chemotherapy for MCD and PEL
[15]. Oral valganciclovir may have a role in secondary pro-
phylaxis for patients with PEL and other KSHV-associated
lymphoproliferative disorders.
Many patients presenting with KSHV-associated lym-
phomas have a history of or concurrent Kaposi’s sarcoma
[6, 11]. Our patient had two episodes of cutaneous Kaposi’s
sarcoma prior to his presentation with lymphoma. A history
of Kaposi’s sarcoma may be an important clue in the workup
of B-symptoms and tumors identiﬁed in solid organs of
patients with HIV. While KSHV viral load has been shown
to have prognostic value in patient’s with known Kaposi’s
sarcoma,thereislimiteddataonthediagnosticorprognostic
utility of KSHV viral loads in patients with suspected or
known non-Hodgkin’s lymphoma [7]. A small study of HIV
patients with KSHV-associated lymphoproliferative disor-
dersfoundthatthosewithlymphomahadhigherKSHVviral
loads than those with MCD [7]. Use of antiretroviral therapy
with viral load suppression, and higher CD4 cell counts have
beenshowntobeprotectivefromKaposi’ssarcomaandnon-
Hodgkin’s lymphoma [16]. This case nicely highlights that
any new mass lesion in a patient with a prior HHV8+ disease
(KS, PEL, or MCD) warrants repeat tissue sampling given
the propensity of multiple histologies to occur in the same
patient, either concurrently or sequentially.
In summary, this case illustrates an unusual presentation
of a KSHV-associated lymphoma, presenting with central
nervous system involvement, with diagnosis established on
an endomyocardial biopsy, in contrast to the more com-
mon KSHV-associated lymphoproliferative disorders: MCD
and PEL. We believe that intermittent nonadherence and
prolonged episodes of immunosuppression may have put
him at risk for KSHV-associated malignant transformation.
Providers should be vigilant for atypical presentations of
common malignancies in patients with prolonged or inter-
mittent immunosuppression.
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